Numinus Wellness (DB:LR23) - Hisse Senedi Fiyatı, Haberler ve Analizler

Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

LR23 Stoklara Genel Bakış

Numinus Wellness Inc. Kanada ve Amerika Birleşik Devletleri'nde psychedelic destekli psikoterapi ürünleri ve hizmetleri sunmaktadır.

Şirket hakkında

LR23 temel anali̇z
Kar Tanesi Skoru
Değerleme	3/6
Gelecekteki Büyüme	5/6
Geçmiş Performans	0/6
Finansal Sağlık	3/6
Temettüler	0/6

Ödüller

Kazançların yılda 60.27% oranında artması öngörülüyor

Rakiplerine ve sektöre kıyasla iyi değerde işlem görüyor

Risk Analizi

Anlamlı bir piyasa değeri yok ( €10M )

1 yıldan az nakit akışı var

Son 3 ayda hisse senedi fiyatı oldukça dalgalıydı

Hissedarlar geçen yıl sulandırıldı

Numinus Wellness Inc. Rakipler

Biofrontera

XTRA:B8FK

€14.5m

MPH Health Care

DB:93M1

€101.0m

SynBiotic

DUSE:SBX

€30.1m

Redx Pharma

DB:0RX

€65.0m

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti Numinus Wellness
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	CA$0.02
52 Haftanın En Yüksek Seviyesi	CA$0.13
52 Haftanın En Düşük Seviyesi	CA$0.015
Beta	1.54
11 Aylık Değişim	-2.44%
3 Aylık Değişim	-0.50%
1 Yıllık Değişim	-82.61%
33 Yıllık Değişim	-95.79%
5 Yıllık Değişim	n/a
Halka arzdan bu yana değişim	-93.88%

Son Haberler & Güncellemeler

Recent updates

Hissedar Getirileri

	LR23	DE Pharmaceuticals	DE Pazar
7D	-2.0%	-3.0%	-1.9%
1Y	-82.6%	-13.2%	12.3%

Getiri vs. Endüstri: LR23 geçen yıl % -11.1 oranında getiri sağlayan German Pharmaceuticals sektörünün gerisinde kaldı.

Getiri vs Piyasa: LR23 geçen yıl % 13.8 oranında getiri sağlayan German Piyasasının altında performans gösterdi.

Fiyat Oynaklığı

Is LR23's price volatile compared to industry and market?
LR23 volatility
LR23 Average Weekly Movement	22.9%
Pharmaceuticals Industry Average Movement	5.4%
Market Average Movement	4.9%
10% most volatile stocks in DE Market	10.7%
10% least volatile stocks in DE Market	2.4%

İstikrarlı Hisse Senedi Fiyatı: LR23 hisse senedi fiyatı son 3 aydır dalgalı bir seyir izliyor.

Zaman İçindeki Volatilite: LR23 'nin haftalık oynaklığı ( 23% ) geçen yıl boyunca sabit kaldı, ancak hala German hisselerinin %75'inden yüksek.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
1964	n/a	Payton Nyquvest	www.numinus.com

Numinus Wellness Inc. Kanada ve Amerika Birleşik Devletleri'nde psychedelic destekli psikoterapi ürünleri ve hizmetleri sunmaktadır. Şirket, Klinik Araştırma Operasyonları, Kanada Klinik Ağı ve ABD Klinik Ağı segmentleri aracılığıyla faaliyet göstermektedir. Klinik Araştırma Operasyonları segmenti, akademik kurumlara ve biyoteknoloji şirketlerine klinik araştırma yönetimi hizmetleri sunmaktadır.

Numinus Wellness Inc. Temel Bilgiler Özeti

Numinus Wellness'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
LR23 temel i̇stati̇sti̇kler
Piyasa değeri	€6.49m
Kazançlar(TTM)	-€17.12m
Gelir(TTM)	€15.09m

0.4x

P/S Oranı

-0.4x

F/K Oranı

LR23 aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
LR23 gelir tablosu (TTM)
Gelir	CA$22.48m
Gelir Maliyeti	CA$15.68m
Brüt Kâr	CA$6.80m
Diğer Giderler	CA$32.31m
Kazançlar	-CA$25.51m

Son Raporlanan Kazançlar

May 31, 2024

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	-0.079
Brüt Marj	30.27%
Net Kâr Marjı	-113.45%
Borç/Özkaynak Oranı	35.4%

LR23 uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

LR23 Stoklara Genel Bakış

Ödüller

Risk Analizi

Numinus Wellness Inc. Rakipler

XTRA:B8FK

€14.5m

DB:93M1

€101.0m

DUSE:SBX

€30.1m

DB:0RX

€65.0m

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

Forecast to breakeven in 2026

Third quarter 2024 earnings released: CA$0.019 loss per share (vs CA$0.028 loss in 3Q 2023)

Numinus Wellness Inc. to Report Q3, 2024 Results on Jul 11, 2024

Numinus Wellness Inc. Appoints Jaime Gerber to Numinus Intelligence Board

MedBright AI Investments Inc. (CNSX:MBAI) executed a letter of intent to acquire MedBright AI Investments Inc. (TSX:NUMI) for CAD 16.2 million in a reverse merger transaction.

Numinus Wellness Comments on FDA Advisory Committee Meeting for Investigational MDMA-Assisted Therapy for PTSD

Recent updates

Forecast to breakeven in 2026

Third quarter 2024 earnings released: CA$0.019 loss per share (vs CA$0.028 loss in 3Q 2023)

Numinus Wellness Inc. to Report Q3, 2024 Results on Jul 11, 2024

Numinus Wellness Inc. Appoints Jaime Gerber to Numinus Intelligence Board

MedBright AI Investments Inc. (CNSX:MBAI) executed a letter of intent to acquire MedBright AI Investments Inc. (TSX:NUMI) for CAD 16.2 million in a reverse merger transaction.

Numinus Wellness Comments on FDA Advisory Committee Meeting for Investigational MDMA-Assisted Therapy for PTSD

Numinus Wellness Receives Health Canada Approval for Study into Group Model for MDMA-Assisted Therapy

Second quarter 2024 earnings released: CA$0.023 loss per share (vs CA$0.028 loss in 2Q 2023)

Numinus Wellness Inc. to Report Q2, 2024 Results on Apr 15, 2024

Numinus Wellness Inc. Submits Clinical Trial Application

Numinus Wellness Inc., Annual General Meeting, May 21, 2024

Numinus Wellness Inc. has completed a Composite Units Offering in the amount of CAD 6 million.

First quarter 2024 earnings released: CA$0.02 loss per share (vs CA$0.024 loss in 1Q 2023)

Numinus Wellness Inc., Annual General Meeting, Feb 26, 2024

Insufficient new directors

Full year 2023 earnings released: CA$0.12 loss per share (vs CA$0.17 loss in FY 2022)

Numinus Wellness Inc. to Report Q4, 2023 Results on Nov 29, 2023

Numinus Wellness Inc. Introduces Its Innovative and Comprehensive Psychedelic Program for Individuals Surging from Mental Distress Associated with Chronic and Serious Illness Through Cedar Clinical Research

Forecast to breakeven in 2026

Third quarter 2023 earnings released: CA$0.028 loss per share (vs CA$0.033 loss in 3Q 2022)

Numinus Wellness Inc. to Report Q3, 2023 Results on Jul 17, 2023

Numinus Wellness Inc. Appoints Nikhil Handa as Chief Financial Officer, Effective from June 15, 2023

Numinus Wellness Inc. Announces Cedar Clinical Research

Numinus Wellness Inc. Announces to Research COMP360 Psilocybin Therapy in Treatment-Resistant Depression as Part of Large Phase 3 Study

Numinus Wellness Inc Aligns Business Initiatives to Prepare for Future Approval of MDMA-Assisted Therapy

Second quarter 2023 earnings released: CA$0.028 loss per share (vs CA$0.038 loss in 2Q 2022)

Numinus Wellness Inc. Receives Clinical Trial Application Approval from Health Canada for Experiential Psychedelic-Assisted Therapy Training Using Psilocybe Cubensis Tea

First quarter 2023 earnings released: CA$0.024 loss per share (vs CA$0.026 loss in 1Q 2022)

Numinus Wellness Inc. to Report Q1, 2023 Results on Jan 16, 2023

Numinus Wellness Inc., Annual General Meeting, Feb 15, 2023

Numinus Wellness Inc. Submits Clinical Trial Application to Health Canada for Experiential Psilocybin Assisted Therapy Training Research

Full year 2022 earnings released: CA$0.21 loss per share (vs CA$0.11 loss in FY 2021)

Numinus Wellness Inc. Reports Impairment of Good Will for the Fourth Quarter Ended August 31, 2022

High number of new and inexperienced directors

Numinus Wellness Inc. Launches Psychedelic-Assisted Therapy for Chronic and Serious Medical Illness

Numinus Develops Mushroom Tea for Use in Psychedelic Research

Numinus Now Offers Ketamine-Assisted Therapy in Toronto

Numinus Wellness Inc. to Report Q4, 2022 Results on Nov 29, 2022

Third quarter 2022 earnings released: CA$0.033 loss per share (vs CA$0.025 loss in 3Q 2021)

Numinus Wellness Inc. to Report Q3, 2022 Results on Jul 14, 2022

Numinus Wellness Inc. Announces Launch of Pilots Mental Health Program for Corporate Clients in Utah

Numinus Wellness Inc. Announces That Its Subsidiary Numinus Bioscience Inc Applies for International Patent Filing of Psychedelics Production Process

Numinus Wellness Inc. (TSX:NUMI) completed the acquisition of Novamind Inc. (OTCPK:NVMD.F).

Numinus Wellness Inc. Receives Health Canada Special Access Program Applicant Approval to Provide Psychedelic-assisted Therapy Treatment

Numinus Announces the Music as Medicine Event Series

High number of new and inexperienced directors

Second quarter 2022 earnings released: CA$0.038 loss per share (vs CA$0.028 loss in 2Q 2021)

Numinus Wellness Inc. (TSX:NUMI) entered into a definitive agreement to acquire Novamind Inc. (OTCPK:NVMD.F) for CAD 21.6 million.

Numinus Wellness Inc. to Report Q2, 2022 Results on Apr 14, 2022

Numinus Wellness Inc. Completes First MDMA Administration in PTSD Trial Sponsored by MAPS

Numinus Wellness Inc. Appoints New Bioscience Advisors to Advance IP Development

First quarter 2022 earnings: EPS in line with expectations, revenues disappoint

Psilocybin and MDMA Get the Green Light for Medical Use in Canada

Numinus Submits Clinical Trial Application for Phase 1 Trial on Proprietary Psilocybin Product

Numinus Wellness Inc.(TSXV:NUMI) dropped from S&P/TSX Venture Composite Index

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Numinus Wellness Inc. (TSXV:NUMI) completed the acquisition of Neurology Centre of Toronto.

Third quarter 2021 earnings released: CA$0.025 loss per share (vs CA$0.035 loss in 3Q 2020)

Numinus Announces Health Canada Approval of MAPS-Sponsored Open Label Study for MDMA-Assisted Therapy for Post-Traumatic Stress Disorder